Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?

Abstract

A recent study has concluded that the use of 123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane single-photon emission computed tomography (123I-FP-CIT SPECT) is cost-effective or cost-saving in patients in whom the diagnosis of Parkinson disease versus essential tremor is uncertain. This conclusion is based on numerous assumptions, not all of which are likely to be universally applicable. The economic advantages associated with the use of 123I-FP-CIT SPECT will vary depending on the prevalence of Parkinson disease in the group of patients with uncertain diagnosis, the cost of usual clinical evaluation including other diagnostic tests, and the consequences of either delaying or inappropriately instituting dopaminergic therapy. The cost-effectiveness of radionuclide scanning is likely to increase in the future if a therapy is developed with a convincing impact on disease progression, the early institution of which confers a better outcome.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Benamer TS et al. (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of 123I-FP-CIT SPECT imaging: the 123I-FP-CIT study group. Mov Disord 15: 503–510

    Article  CAS  Google Scholar 

  2. Antonini A et al. (2008) Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord [10.1002/mds.22278]

  3. Dodel RC et al. (2003) Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord 18 (Suppl 7): S52–S62

    Article  Google Scholar 

  4. Jankovic J et al. (2000) The evolution of diagnosis in early Parkinson disease: Parkinson Study Group. Arch Neurol 57: 369–372

    Article  CAS  Google Scholar 

  5. Olanow CW and Rascol O (2008) Early rasagiline treatment slows UPDRS decline in the ADAGIO delayed start study. Ann Neurol 64 (Suppl 12): S3

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author has acted as a consultant and received honoraria from Teva Pharmaceutical Industries.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stoessl, A. Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?. Nat Rev Neurol 5, 10–11 (2009). https://doi.org/10.1038/ncpneuro0986

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0986

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing